Last A$0.39 AUD
Change Today +0.02 / 5.41%
Volume 45.0K
ELX On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 12:20 AM 07/29/14 All times are local (Market data is delayed by at least 15 minutes).

ellex medical lasers ltd (ELX) Snapshot

Open
A$0.39
Previous Close
A$0.37
Day High
A$0.39
Day Low
A$0.39
52 Week High
01/22/14 - A$0.47
52 Week Low
07/30/13 - A$0.25
Market Cap
42.0M
Average Volume 10 Days
24.5K
EPS TTM
A$-0.0077
Shares Outstanding
107.6M
EX-Date
12/3/02
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ELLEX MEDICAL LASERS LTD (ELX)

Related News

No related news articles were found.

ellex medical lasers ltd (ELX) Related Businessweek News

No Related Businessweek News Found

ellex medical lasers ltd (ELX) Details

Ellex Medical Lasers Limited designs, manufactures, markets, and sells lasers and diagnostic ultrasound systems for ophthalmologists to diagnose and treat eye diseases. The company offers Photodisruptors under the Ultra Q and Super Q names for the treatment of secondary cataracts; Photocoagulators under the Integre Duo, Integre, Solitaire, Integre Pro, and Integre Yellow names to treat age-related macular degeneration (AMD) and diabetic retinal diseases; and Selective Laser Trabeculoplasty Photoregeneration systems under the Tango and Solo names for the treatment of glaucoma, as well as Diagnostic Ultrasound Systems under the Eye Cubed name to visualize anatomy and structures below the surface of the retina. It also develops Ellex Retinal Rejuvenation Therapy, a laser therapy that is in clinical trials for the treatment of AMD and diabetic retinopathy. The company sells its products directly to end-user customers, as well as through independent third-party distributors in Australia, the United States, Europe, the Middle East, Asia, South America, and internationally. Ellex Medical Lasers Limited is based in Adelaide, Australia.

201 Employees
Last Reported Date: 08/29/13

ellex medical lasers ltd (ELX) Top Compensated Officers

Group Chief Executive Officer
Total Annual Compensation: A$299.2K
Founder, Executive Chairman, Technical Direct...
Total Annual Compensation: A$45.0K
Vice President of Adavnced Research
Total Annual Compensation: A$180.9K
Compensation as of Fiscal Year 2013.

ellex medical lasers ltd (ELX) Key Developments

Ellex Medical Lasers Limited Announces Further Results for 2RT Treatment of Early AMD

Ellex Medical Lasers Limited announced the 24-month follow up of the pilot study to investigate the efficacy of the company's proprietary Retinal Rejuvenation Therapy (2RT) in the treatment of early Age-Related Macular Degeneration (AMD) has been released and published in a summary form at the recent Association for Research in Vision and Ophthalmology (ARVO) 2014 conference in Orlando, Florida. This 24-month data, presented as a scientific poster on 9 May 2014 at ARVO by Associate Professor Erica L Fletcher MScOptom, PhD, Department of Anatomy and Neuroscience, The University of Melbourne, is a follow up to the 12-month data for the "2RT for Early AMD" pilot study (ACTRN 1260900E1056280) that was conducted over 2009 to 2011 at the Centre for Eye Research Australia (CERA) under Professor Robyn Guymer, MB, BS PhD, FRANZCO, Head of Macular Research at CERA. In the pilot study, 51 patients with intermediate AMD received a single treatment to one eye with the 2RT laser. Drusen area in each eye was graded at baseline, 12 and 24 months later. Changes in drusen area in the treated eyes were compared with a natural history AMD cohort of similar age range and clinical AMD severity. Drusen are a key important risk factor for progression of AMD to its blinding end stage. The 2RT laser treatment reduced drusen area in 35-40% of eyes following twelve and 24 months (compared to 5-11 % of eyes in a natural history cohort). This is consistent with the outcome of the 12-month data. Unlike currently marketed AMD treatments, which only address advanced or late-stage complications of the disease, Ellex's 2RT technology is designed to offer treatment earlier in the disease process, with the aim of slowing or reversing its progression. Pre-clinical studies were also conducted by A/Professor Fletcher to validate a mouse model of AMD and compare it with human data.

Ellex Medical Lasers Limited Reports Earnings Results for the Six Months Ended December 31, 2013; Provides Sales Guidance for the Second Half of 2014

Ellex Medical Lasers Limited reported earnings results for the six months ended December 31, 2013. For the period, the company reported EBITDA of $1.4 million against $0.9 million a year ago. EBIT was $1.2 million against $0.2 million a year ago. Reported NPAT was $0.4 million against $0.1 million a year ago. EPS was 0.36 cents against 0.04 cents a year ago. Underlying EBITDA of approx. $1.9 million, up 110% on pcp. Net cash flow was $3.6 million. Sales continue to accelerate with 8 month year to date sales growth of +21% on pcp vs first half growth of 17.7%. This trend is expected to continue for the remainder of second half of 2014.

Ellex Medical Lasers Limited Reports Earnings Results for the Six Months Ended December 31, 2013

Ellex Medical Lasers Limited reported earnings results for the six months ended December 31, 2013. For the period, profit before tax was $654,000, recorded on revenues of $25.9 million. This compares with a profit before tax of $59,000 and revenues of $22.0 million for the six months ended December 31, 2012. The 18% increase in Revenue was primarily attributable to growth in sales in the USA following the introduction in July 2013 of Ellex's Selective Laser Trabeculoplasty (SLT) range of ophthalmic lasers for the treatment of glaucoma. Cash generated from operations was $1.3 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ELX:AU A$0.39 AUD +0.02

ELX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Carl Zeiss Meditec AG €22.57 EUR +0.046
Iridex Corp $7.85 USD +0.18
Quantel SA €3.50 EUR +0.01
Synergetics USA Inc $3.10 USD +0.02
Topcon Corp ¥2,390 JPY +24.00
View Industry Companies
 

Industry Analysis

ELX

Industry Average

Valuation ELX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.9x
Price/Book 1.1x
Price/Cash Flow 67.9x
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELLEX MEDICAL LASERS LTD, please visit www.ellex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.